Butyzamide 

Butyzamide (GMP) is Butyzamide (HY-148748) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Butyzamide is an orally active activator of Mpl, a thrombopoietin (TPO) receptor. Butyzamide increases the phosphorylation level of JAK2, STAT3, STAT5 and MAPK. Butyzamide increases the level of platelets in mouse xenotransplantation assay^[1].

Butyzamide (GMP) (3 μM; 15 min) induces the phosphorylation of JAK2, STAT3, STAT5 and MAPK in Ba/F3-hMpl cells^[1].
Butyzamide (GMP) (3 μM; 48 h) induces colony-forming unit-megakaryocyte and polyploid meggakaryocytes from human CD34⁺ hematopoietic progenitor cellls^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Butyzamide (GMP) (10 mg/kg, 50 mg/kg; p.o.; once daily for 20 days) increases platelets in NOG mice transplanted with human fetal liver-derived CD34⁺ cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

591.55

C₂₉H₃₂Cl₂N₂O₅S

1110767-45-7

CCCOC(C(C)(C)C)C1=CC=CC(C2=CSC(NC(C3=CC(Cl)=C(/C=C(C(O)=O)\C)C(Cl)=C3)=O)=N2)=C1OC

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Nogami W, et al. The effect of a novel, small non-peptidyl molecule butyzamide on human thrombopoietin receptor and megakaryopoiesis. Haematologica. 2008 Oct;93(10):1495-504.  [Content Brief]